Navigation Links
Post-Hoc Data Show Daily Activity Participation, Independence and Sleep Quality Improved in Adults with Moderate to Severe Rheumatoid Arthritis After Treatment with ORENCIA(R) (Abatacept)
Date:11/12/2007

in the placebo group (p-value less than 0.0001) sleep problems Index I was -9.5 in the ORENCIA group and -1.4 in the placebo group (p-value less than 0.0001) and Index II was -9.8 in the ORENCIA group and -2.1 in the placebo group (p-value less than 0.0001). MOS-sleep scales measuring awakened short of breath or with headache and snoring were not significantly different in the ATTAIN group. In the AIM study, measurement of sleep disturbance in the ORENCIA group was -13.0 and -8.9 in the placebo group (p-value equals 0.0197), sleep problems Index I was -9.4 in the ORENCIA group and -6.7 in the placebo group (p-value equals 0.0476) and Index II was -10.4 in the ORENCIA group and -7.3 in the placebo group (p-value equals 0.0173). MOS-sleep scales measuring awakened short of breath or with headache, snoring, adequacy or drowsiness were not significantly different in the AIM group.

About AIM and ATTAIN

AIM was a Phase III multi-center, randomized, double-blind, placebo- controlled trial with 652 patients treated at baseline who had active RA despite MTX therapy (638 included in efficacy analyses). The study was double-blind through one year, followed by an ongoing, open-label, long-term extension study. A total of 376 (from the original 424) patients in the group treated with ORENCIA(R) (abatacept) entered the long-term extension study. Additional DMARDs, non-steroidal anti-inflammatory drugs (NSAIDs), and aspirin were added and/or adjusted at the discretion of the investigator in the long- term extension study. Primary reasons for discontinuation in the long-term extension studies were adverse events, withdrawal of consent, and lack of efficacy.

Primary endpoints were ACR 20 at six months ORENCIA vs. placebo (67.9 percent vs. 39.7 percent, respectively; p-value less than 0.001), clinically significant improvement in HAQ-DI at one year (63.7 percent vs. 39.3 percent, respectively; p-value less than 0.001), erosion score at one year (mean change from bas
'/>"/>

SOURCE Bristol-Myers Squibb Company
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy
2. New Data Published in Neurology Show Once-Daily Lamictal XR Significantly Reduced Partial Seizures in Patients with Epilepsy
3. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
4. Potent Hepatitis C Virus Inhibitors Show Efficacy and Potential for Once Daily Dosing in Preclinical Studies
5. ISTA Pharmaceuticals Presents Results from Two Phase III Clinical Trials of Xibrom(TM) QD (Once-daily) Formulation at the American Academy of Ophthalmology Annual Meeting
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. R7128 Demonstrates Safety and Potent Antiviral Activity in HCV-Infected Patients
8. Oritavancin Demonstrates Superior In Vitro Activity to Vancomycin and Metronidazole Against C. Difficile Bacteria
9. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
10. Oritavancin Demonstrates Potent and Rapid In Vitro Activity Against MRSA, VRE and Other Strains of Resistant Bacteria
11. Proteolix Initiates Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... Corporation (NASDAQ: CYTR ), a biopharmaceutical research and ... for the three months ended June 30, 2015, and ... milestones for its clinical development programs. "The ... CytRx. Enrollment in our ongoing pivotal global Phase 3 ... continues on track to be completed in the first ...
(Date:8/3/2015)... 2015 Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK ) ... Quarter 2015 Investor Conference Call and webcast at 4:30 p.m., ... call will cover an update on Merrimack,s progress as ... A press release detailing the information to be discussed ... Monday, August 10. Investors and the general public are ...
(Date:8/3/2015)... Aug. 3, 2015  Celsion Corporation (NASDAQ: ... host a conference call to discuss its second ... on its development programs for ThermoDox®, its proprietary ... acquired technology platforms, TheraPlas™ and TheraSilence™, in immunotherapy ... Monday, August 10, 2015. To participate in the ...
Breaking Medicine Technology:CytRx Reports 2015 Second Quarter Financial Results 2CytRx Reports 2015 Second Quarter Financial Results 3CytRx Reports 2015 Second Quarter Financial Results 4CytRx Reports 2015 Second Quarter Financial Results 5CytRx Reports 2015 Second Quarter Financial Results 6CytRx Reports 2015 Second Quarter Financial Results 7CytRx Reports 2015 Second Quarter Financial Results 8CytRx Reports 2015 Second Quarter Financial Results 9CytRx Reports 2015 Second Quarter Financial Results 10CytRx Reports 2015 Second Quarter Financial Results 11CytRx Reports 2015 Second Quarter Financial Results 12CytRx Reports 2015 Second Quarter Financial Results 13CytRx Reports 2015 Second Quarter Financial Results 14Merrimack Pharmaceuticals Announces Timing of Second Quarter 2015 Investor Conference Call 2Celsion Corporation to Hold Second Quarter 2015 Financial Results Conference Call on Monday, August 10, 2015 2
... 29, 2011 Robbins & Myers, Inc. ... sale of its Romaco businesses to a group of ... private equity investment firm.  Total consideration was approximately euro ... of cash and euro 4 million of assumed liabilities ...
... SILVER SPRING, Md., April 29, 2011 Don,t let expired ... dispose of them properly to prevent them from harming others. ... part in the second annual National Prescription Drug Take-Back Day, ... View a slideshow and read a Consumer Update ...
Cached Medicine Technology:
(Date:8/4/2015)... ... August 04, 2015 , ... Oriental ... and crafts, toys, novelties, and school supplies, has developed engaging and affordable teacher ... exclusive collection includes student rewards, classroom decorations, crafts and educational resources featuring ...
(Date:8/4/2015)... ... August 04, 2015 , ... It is National Psoriasis Awareness Month, and we ... symptoms such as dry, itching, burning or soreness of skin that may crack or ... they find what’s right for them. Then, what is effective may stop working, so ...
(Date:8/4/2015)... York, NY (PRWEB) , ... August 04, 2015 , ... ... all but universal, though the desire for invasive surgery to achieve this ideal is ... offer the results people crave without the high cost or lengthy recovery time, according ...
(Date:8/4/2015)... ... ... Nathan’s Famous was recently featured on NewsWatch as part of ... an impact in their industry. Andrew Tropeano, the host of NewsWatch and business expert, ... now offers a 50% Reduced Fat All-Beef Frank variety and is celebrating summer ...
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... ... developing the most recent episode which spotlights treating depression. Depression affects millions of ... disease, "In America" wants to inform and enlighten viewers with the latest segment ...
Breaking Medicine News(10 mins):Health News:Oriental Trading Company Brings The World of Eric Carle Characters to Educators Through Classroom Supplies 2Health News:Oriental Trading Company Brings The World of Eric Carle Characters to Educators Through Classroom Supplies 3Health News:USA Medical Card Offers a Solution During National Psoriasis Awareness Month 2Health News:USA Medical Card Offers a Solution During National Psoriasis Awareness Month 3Health News:Considering fillers, tighteners or laser resurfacing? 2Health News:Considering fillers, tighteners or laser resurfacing? 3Health News:Considering fillers, tighteners or laser resurfacing? 4Health News:Celebrate Summer with Nathan’s Famous Original Selfie Sweepstakes 2Health News:Celebrate Summer with Nathan’s Famous Original Selfie Sweepstakes 3
... and ,Samantha Who?, to be Honored at Donate Life Film ... June 5 On June 13, Donate Life Hollywood will ... "Samantha Who?" with its first annual Inspire Award. This honor, ... be presented at the culmination of the daylong Donate Life ...
... evident with seniors, researchers say , FRIDAY, June 5 (HealthDay ... new generation of video games that require users to get ... bit more fit. , New research suggests that several exercise-based ... equal to that of light jogging. , And seniors in ...
... Joseph F. Finn, Jr., C.P.A. ("Finn") announced today ... Cancer Research Ltd., Brussels Branch. The statement is quoted ... product candidate, GCS-100, is a carbohydrate molecule which inhibits the ... a broad range of human cancers. Prospect reported that ...
... show, , FRIDAY, June 5 (HealthDay News) -- One reason ... not that interesting. But what if you could dance your ... suggest that you just might be able to do that. ... meeting in Seattle, one study found that salsa dancing could ...
... region are ready to prescribe and dispense medications electronically , ... of Spain and IBM (NYSE: IBM ) have ... where health centres and pharmacies are now computerised and able ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20090416/IBMLOGO ...
... are experiencing onerous fatigue four months after the infarction. The ... infarction as a sign of chronic illness, those who experience ... that the illness has a large impact on their life. ... Sahlgrenska Academy, University of Gothenburg, Sweden. Just over 200 ...
Cached Medicine News:Health News:ABC-TV Gets It Right According to Organ Donation Community 2Health News:Interactive Video Games Offer Exercise Benefits 2Health News:Interactive Video Games Offer Exercise Benefits 3Health News:Ludwig Institute of Cancer Research Ltd., Brussels Branch, Issues Statement Concerning Prospect Therapeutics Inc's. GCS-100 Molecule 2Health News:Finding Fitness on the Dance Floor 2Health News:Finding Fitness on the Dance Floor 3Health News:Spain's Regional Extremadura Government Launches Electronic Prescription System With IBM 2Health News:Fatigue common after myocardial infarction 2